⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for gliosarcoma

Every month we try and update this database with for gliosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeNCT00672243
Glioblastoma
Gliosarcoma
Erlotinib + sir...
18 Years - Duke University
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade GliomaNCT02168270
Anaplastic Astr...
Anaplastic Olig...
Anaplastic Olig...
Glioblastoma
Gliosarcoma
ascorbic acid
temozolomide
quality-of-life...
laboratory biom...
19 Years - University of Nebraska
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With GlioblastomaNCT04091503
Glioma, Maligna...
Gliosarcoma
Astrocytoma of ...
Intranasal Modi...
21 Years - 70 YearsCenter Trials & Treatment Europe
Phase II Study of Temozolomide in Newly Diagnosed GlioblastomaNCT00365222
Glioblastoma
Gliosarcoma
Temozolomide
70 Years - H. Lee Moffitt Cancer Center and Research Institute
Ph I Dasatinib + Erlotinib in Recurrent MGNCT00609999
Glioblastoma
Gliosarcoma
Erlotinib and D...
18 Years - Duke University
Phase II Study of Temozolomide in Newly Diagnosed GlioblastomaNCT00365222
Glioblastoma
Gliosarcoma
Temozolomide
70 Years - H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab and Standard Therapy in Treating Patients With GlioblastomaNCT03197506
Glioblastoma
Gliosarcoma
Supratentorial ...
External Beam R...
Laboratory Biom...
Pembrolizumab
Radiation Thera...
Temozolomide
Therapeutic Con...
18 Years - Mayo Clinic
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryNCT01814813
Recurrent Gliob...
Recurrent Adult...
Gliosarcoma
HSPPC-96
bevacizumab
18 Years - Alliance for Clinical Trials in Oncology
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBMNCT00597493
Recurrent Gliob...
Sorafenib and T...
18 Years - Duke University
Pharmacokinetics (PK) Study of AC480 for Recurrent GliomaNCT00979173
Glioma
AC480
18 Years - Duke University
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent GlioblastomaNCT01582152
Brain Neoplasms
Central Nervous...
TPI287
Bevacizumab
18 Years - M.D. Anderson Cancer Center
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerNCT03107780
Glioblastoma
Gliosarcoma
MGMT-Unmethylat...
Recurrent Gliob...
Biospecimen Col...
Magnetic Resona...
Navtemadlin
Radiation Thera...
18 Years - National Cancer Institute (NCI)
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBMNCT00612989
Glioblastoma
Gliosarcoma
Temodar and O6-...
18 Years - Duke University
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaNCT01480479
Glioblastoma
Small Cell Glio...
Giant Cell Glio...
Gliosarcoma
Glioblastoma Wi...
Rindopepimut (C...
Temozolomide
KLH
18 Years - Celldex Therapeutics
Pembrolizumab and Standard Therapy in Treating Patients With GlioblastomaNCT03197506
Glioblastoma
Gliosarcoma
Supratentorial ...
External Beam R...
Laboratory Biom...
Pembrolizumab
Radiation Thera...
Temozolomide
Therapeutic Con...
18 Years - Mayo Clinic
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV GliomasNCT00031083
Glioblastoma Mu...
Anaplastic Astr...
Oligoastrocytom...
Gliosarcoma
Interferon-beta
18 Years - Biogen
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaNCT02311920
Gliosarcoma
Supratentorial ...
Ipilimumab
Laboratory Biom...
Nivolumab
Temozolomide
18 Years - National Cancer Institute (NCI)
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)NCT00735436
Malignant Gliom...
Glioblastoma Mu...
Gliosarcoma
Gliadel/Avastin...
18 Years - Duke University
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and OsteosarcomaNCT03478462
Pediatric Solid...
Pediatric Lymph...
Pediatric Brain...
DIPG
Neuroblastoma
Ewing Sarcoma
Rhabdomyosarcom...
Osteosarcoma
CLR 131
2 Years - 25 YearsCellectar Biosciences, Inc.
AMG 102 and Avastin for Recurrent Malignant GliomaNCT01113398
Glioblastoma Mu...
Gliosarcoma
AMG 102
Avastin
18 Years - Duke University
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and GliosarcomasNCT00612339
Glioblastoma
Gliosarcoma
Avastin and Tem...
18 Years - Duke University
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaNCT02599090
Glioblastoma
Gliosarcoma
Temozolomide
Radiation
Sorafenib
18 Years - M.D. Anderson Cancer Center
Natural Progesterone for the Treatment of Recurrent GlioblastomaNCT05091866
Gliosarcoma
Recurrent Gliob...
Quality-of-Life...
Questionnaire A...
Therapeutic Pro...
18 Years - Emory University
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeNCT00672243
Glioblastoma
Gliosarcoma
Erlotinib + sir...
18 Years - Duke University
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryNCT01814813
Recurrent Gliob...
Recurrent Adult...
Gliosarcoma
HSPPC-96
bevacizumab
18 Years - Alliance for Clinical Trials in Oncology
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or GliosarcomaNCT04555577
Glioblastoma
Gliosarcoma
Peposertib
Radiation Thera...
Resection
Temozolomide
18 Years - M.D. Anderson Cancer Center
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant GliomasNCT01257594
Brain Cancer
erlotinib
Cytoreductive S...
18 Years - Columbia University
Ph II Bevacizumab + Etoposide for Pts w Recurrent MGNCT00612430
Glioblastoma
Gliosarcoma
Bevacizumab and...
18 Years - Duke University
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabNCT02330562
Malignant Gliom...
Glioblastoma
MRZ
BEV
18 Years - Celgene
Multi-site Validation and Application of a Consensus DSC-MRI ProtocolNCT03401866
Glioblastoma Mu...
Gliosarcoma
DSC-MRI
18 Years - St. Joseph's Hospital and Medical Center, Phoenix
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueNCT05756985
Glioblastoma
Glioblastoma Mu...
Gliosarcoma
Specimen Collec...
18 Years - Baptist Health South Florida
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma MultiformeNCT00883298
Recurrent Gliob...
Recurrent Glios...
temozolomide an...
18 Years - 83 YearsCenter for Neurosciences, Tucson
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerNCT03107780
Glioblastoma
Gliosarcoma
MGMT-Unmethylat...
Recurrent Gliob...
Biospecimen Col...
Magnetic Resona...
Navtemadlin
Radiation Thera...
18 Years - National Cancer Institute (NCI)
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsNCT01609790
Giant Cell Glio...
Glioblastoma
Gliosarcoma
Oligodendroglio...
Recurrent Brain...
Recurrent Gliob...
Bevacizumab
Laboratory Biom...
Pharmacological...
Placebo Adminis...
Trebananib
18 Years - National Cancer Institute (NCI)
Bevacizumab Beyond Progression (BBP)NCT01740258
Malignant Gliom...
Grade 4 Maligna...
Glioblastoma
Gliosarcoma
Radiation Thera...
Temozolomide
Bevacizumab
18 Years - Duke University
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaNCT01957956
Giant Cell Glio...
Glioblastoma
Gliosarcoma
Laboratory Biom...
Malignant Gliom...
Temozolomide
18 Years - Mayo Clinic
Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research ProtocolsNCT00035373
Glioblatoma
Gliosarcoma
Anaplastic Astr...
Oligodendroglio...
Anaplastic Olig...
18 Years - 100 YearsNational Institutes of Health Clinical Center (CC)
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade GliomaNCT02168270
Anaplastic Astr...
Anaplastic Olig...
Anaplastic Olig...
Glioblastoma
Gliosarcoma
ascorbic acid
temozolomide
quality-of-life...
laboratory biom...
19 Years - University of Nebraska
SCH-900105 in Recurrent GlioblastomaNCT01189513
Glioblastoma
SCH 900105
18 Years - M.D. Anderson Cancer Center
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation TherapyNCT01430351
Glioblastoma
Gliosarcoma
Supratentorial ...
Mefloquine
Memantine Hydro...
Metformin Hydro...
Temozolomide
18 Years - M.D. Anderson Cancer Center
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNCT05864534
Newly Diagnosed...
Glioblastoma, I...
Gliosarcoma
Glioblastoma Mu...
Balstilimab
Botensilimab
Liposomal Doxor...
Sonocloud-9 (SC...
18 Years - Northwestern University
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaNCT03014804
Giant Cell Glio...
Gliosarcoma
Oligodendroglio...
Recurrent Gliob...
Small Cell Glio...
autologous dend...
Laboratory Biom...
Nivolumab
Quality-of-Life...
Questionnaire A...
18 Years - 75 YearsJonsson Comprehensive Cancer Center
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + IrinotecanNCT00613028
Glioblastoma
Gliosarcoma
Temo + Avastin
VP-16 + Avastin
18 Years - Duke University
Ph I Oral Topotecan and Temozolomide for Patients With Malignant GliomasNCT00610571
Glioblastoma
Gliosarcoma
Anaplastic Astr...
Oral Topotecan ...
18 Years - Duke University
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + IrinotecanNCT00613028
Glioblastoma
Gliosarcoma
Temo + Avastin
VP-16 + Avastin
18 Years - Duke University
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2NCT01082926
Anaplastic Astr...
Anaplastic Epen...
Anaplastic Meni...
Anaplastic Olig...
Brain Stem Glio...
Ependymoblastom...
Giant Cell Glio...
Glioblastoma
Gliosarcoma
Grade III Menin...
Meningeal Heman...
Mixed Glioma
Pineal Gland As...
Brain Tumor
therapeutic all...
aldesleukin
laboratory biom...
positron emissi...
18 Years - 70 YearsCity of Hope Medical Center
A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasNCT01837862
Pilomyxoid Astr...
Pilocytic Astro...
Glioma, Astrocy...
Optic Nerve Gli...
Pleomorphic Xan...
Glioblastoma Mu...
Anaplastic Astr...
Gliosarcoma
Diffuse Intrins...
DIPG
Low-grade Gliom...
Brainstem Gliom...
Mebendazole
Vincristine
Carboplatin
Temozolomide
Bevacizumab
Irinotecan
1 Year - 21 YearsNorthwell Health
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With GlioblastomaNCT04091503
Glioma, Maligna...
Gliosarcoma
Astrocytoma of ...
Intranasal Modi...
21 Years - 70 YearsCenter Trials & Treatment Europe
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase INCT00671801
Malignant Gliom...
Irinotecan
Lenalidomide
18 Years - M.D. Anderson Cancer Center
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain TumorsNCT02052648
Glioblastoma Mu...
Glioma
Gliosarcoma
Malignant Brain...
Indoximod
Temozolomide
Bevacizumab
Stereotactic Ra...
16 Years - Lumos Pharma
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaNCT04216329
Gliosarcoma
Newly Diagnosed
Glioblastoma
Selinexor
Temozolomide
Generic Radiati...
18 Years - National Institutes of Health Clinical Center (CC)
Phase I/II Cabazitaxel for Recurrent Malignant GliomaNCT01740570
Brain Cancer
Cabazitaxel
18 Years - M.D. Anderson Cancer Center
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase INCT00671801
Malignant Gliom...
Irinotecan
Lenalidomide
18 Years - M.D. Anderson Cancer Center
Sunitinib in Sarcomas of the Central Nervous SystemNCT03641326
Gliosarcoma
Central Nervous...
Sunitinib
wGT3x-BT
18 Years - National Institutes of Health Clinical Center (CC)
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaNCT04216329
Gliosarcoma
Newly Diagnosed
Glioblastoma
Selinexor
Temozolomide
Generic Radiati...
18 Years - National Institutes of Health Clinical Center (CC)
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or GliosarcomaNCT01149850
Giant Cell Glio...
Glioblastoma
Gliosarcoma
bevacizumab
temozolomide
laboratory biom...
immunohistochem...
microarray anal...
DNA methylation...
70 Years - Jonsson Comprehensive Cancer Center
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)NCT01110876
Brain Cancer
Glioblastoma Mu...
Vorinostat
Erlotinib
Temozolomide
18 Years - M.D. Anderson Cancer Center
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade GliomaNCT01095094
Brain Tumor
Anaplastic Astr...
Anaplastic Epen...
Anaplastic Olig...
Brain Stem Glio...
Giant Cell Glio...
Glioblastoma
Gliosarcoma
Mixed Glioma
ritonavir
lopinavir
18 Years - Case Comprehensive Cancer Center
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaNCT02101905
Anaplastic Astr...
Anaplastic Epen...
Anaplastic Olig...
Gliosarcoma
Mixed Glioma
Recurrent Adult...
Recurrent Gliob...
Laboratory Biom...
Lapatinib
Lapatinib Ditos...
Pharmacological...
Therapeutic Con...
18 Years - National Cancer Institute (NCI)
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent GlioblastomaNCT02743078
Glioblastoma
Glioma
Gliosarcoma
Bevacizumab
TTFields Therap...
22 Years - RTOG Foundation, Inc.
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With GlioblastomaNCT02661282
Cytomegalovirus...
Glioblastoma
Gliosarcoma
Malignant Gliom...
Recurrent Brain...
Recurrent Gliob...
Autologous Cyto...
Laboratory Biom...
Temozolomide
Therapeutic Con...
18 Years - M.D. Anderson Cancer Center
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaNCT02709226
Astrocytoma, Gr...
Giant Cell Glio...
Glioblastoma Mu...
Gliosarcoma
Radiation
18 Years - National Institutes of Health Clinical Center (CC)
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)NCT00671970
Glioblastoma
Gliosarcoma
Bevacizumab and...
18 Years - Duke University
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or GliosarcomaNCT00525525
Glioblastoma
Gliosarcoma
Bevacizumab
Tarceva
Temozolomide
18 Years - University of California, San Francisco
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasNCT01514201
Anaplastic Astr...
Brain Stem Glio...
Childhood Mixed...
Fibrillary Astr...
Giant Cell Glio...
Glioblastoma
Gliosarcoma
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
Untreated Child...
3-Dimensional C...
Intensity-Modul...
Laboratory Biom...
Pharmacological...
Temozolomide
Veliparib
- 21 YearsNational Cancer Institute (NCI)
131-I-TM-601 Study in Adults With Recurrent High-Grade GliomaNCT00114309
Malignant Gliom...
Glioblastoma Mu...
GBM
Anaplastic Astr...
Oligo-Astrocyto...
Gliosarcoma
131-I-TM-601
131I-TM601
18 Years - TransMolecular
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant GliomaNCT00613054
Glioblastoma
Gliosarcoma
Zactima, Gleeve...
18 Years - Duke University
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeNCT00165477
Glioblastoma
Gliosarcoma
Malignant Gliom...
lenalidomide
Radiation
18 Years - Dana-Farber Cancer Institute
Ph I Oral Topotecan and Temozolomide for Patients With Malignant GliomasNCT00610571
Glioblastoma
Gliosarcoma
Anaplastic Astr...
Oral Topotecan ...
18 Years - Duke University
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)NCT00087451
Malignant Gliom...
Glioblastoma
Gliosarcoma
AP23573
18 Years - Merck Sharp & Dohme LLC
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)NCT00615927
Glioblastoma
Gliosarcoma
Imatinib Mesyla...
18 Years - Duke University
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaNCT00734526
Glioblastoma
Gliosarcoma
Temozolomide
Radiation
Sorafenib
18 Years - M.D. Anderson Cancer Center
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaNCT03014804
Giant Cell Glio...
Gliosarcoma
Oligodendroglio...
Recurrent Gliob...
Small Cell Glio...
autologous dend...
Laboratory Biom...
Nivolumab
Quality-of-Life...
Questionnaire A...
18 Years - 75 YearsJonsson Comprehensive Cancer Center
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant GliomasNCT00612651
Gliosarcoma
Glioblastoma
Anaplastic Astr...
Temodar and SCH...
18 Years - Duke University
Radiosurgery Plus Bevacizumab in GlioblastomaNCT01086345
Glioblastoma
Gliosarcoma
Brain Tumor
radiosurgery
bevacizumab
irinotecan hydr...
18 Years - Case Comprehensive Cancer Center
BIBF 1120 for Recurrent High-Grade GliomasNCT01380782
Glioblastoma
Gliosarcoma
Anaplastic Astr...
Anaplastic Olig...
Anaplastic Olig...
BIBF 1120
18 Years - Dana-Farber Cancer Institute
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed GlioblastomaNCT00936052
Glioblastomas
Gliosarcoma
Hyperbaric Oxyg...
18 Years - Neurological Surgery, P.C.
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaNCT03275558
Recurrent Gliob...
Gliosarcoma
Anaplastic Glio...
Axitinib 1 MG
Sunitinib 5 MG
Pazopanib 5 MG
18 Years - 80 YearsCenter Trials & Treatment
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or GliosarcomaNCT01149850
Giant Cell Glio...
Glioblastoma
Gliosarcoma
bevacizumab
temozolomide
laboratory biom...
immunohistochem...
microarray anal...
DNA methylation...
70 Years - Jonsson Comprehensive Cancer Center
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated GlioblastomaNCT05095376
Glioblastoma
Gliosarcoma
Lomustine
Photon Beam Rad...
Quality-of-Life...
Questionnaire A...
Temozolomide
18 Years - 70 YearsNRG Oncology
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: